2021 Sanofi iAwards: Call–for–Proposals

Sanofi iAwards program is a multi-institutional academic partnership program designed to collaborate with academic investigators to quickly move promising early stage, disease relevant, innovative research towards the clinic. Through this program, Sanofi aims to fund innovative and translational research ideas that can contribute to our early stage pipeline and ultimately benefit patients.

Each selected proposal will receive:

- $125,000 research funding (including institutional indirect costs) for 12 months
- Sanofi scientific expertise and guidance
- In-kind resources such as reagents, tool compounds, etc. may be provided
- Successful projects could be converted to SRAs and receive additional funding for 2-3 years

Sanofi iAwards General Timeline

<table>
<thead>
<tr>
<th>Action</th>
<th>Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission of non-confidential summary by Institution</td>
<td>May 31, 2021</td>
</tr>
<tr>
<td>Invitation of pre-proposal submission</td>
<td>June 23, 2021</td>
</tr>
<tr>
<td>Submission of pre-proposal by Institution</td>
<td>June 30, 2021</td>
</tr>
<tr>
<td>Notification by Sanofi of pre-proposals chosen to be pursued as Full Proposals</td>
<td>July 9, 2021</td>
</tr>
<tr>
<td>Completion and submission of Full Proposals</td>
<td>July 30, 2021</td>
</tr>
<tr>
<td>JSSC meets to review Full Proposals</td>
<td>September 2021*</td>
</tr>
<tr>
<td>Institution informed of JSSC funding decisions</td>
<td>October 2021*</td>
</tr>
</tbody>
</table>

* subject to change

Confidential- please do not distribute outside of your institution
Areas of Interest
Sanofi is seeking the following type of opportunities in the therapeutics areas provided below:

- New and actionable knowledge about disease relevant targets, pathways and mechanisms
- Early stage compounds or biologics targeting novel disease mechanisms
- New models for validating disease relevant targets
- Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
- Novel therapeutic modalities

**IMMUNOLOGY & INFLAMMATION**
- Diseases associated with dysregulated Type 2 immune responses including Atopic Dermatitis and Asthma
- Rheumatological disorders including Lupus Erythematosus, Rheumatoid Arthritis, psoriatic arthritis, and Ankylosing spondylitis
- Autoimmune sequelae of checkpoint inhibition
- Co-stimulation pathways in autoimmune and allergic diseases
- Systems Immunology and single (immune) cell analysis
- Immuno-metabolism

**RARE DISEASES**
- Novel targets, models and therapeutic concepts for rare muscular dystrophies, kidney, metabolic, bleeding, and lysosomal storage diseases
- Immunogenicity of FVIII and mechanisms of tolerance induction
- Structural understanding of blood coagulation factors complexes on phospholipid surfaces
- Role complement cascade in the pathophysiology of rare and common disorders, including kidney, blood, eye, and CNS diseases

**NEUROLOGICAL DISORDERS**
- Novel targets, assays, models and therapeutic concepts for proteinopathies, in particular for synucleinopathies, tauopathies and TDP-43 driven diseases
- Novel targets and mechanisms to achieve neuroprotection in neurodegenerative diseases including MS, PD and ALS/FTD
- Novel approaches to address nucleotide repeat expansion diseases, including small molecules
- Novel targets, models and therapeutic concepts for neuromuscular diseases
- Novel targets and therapeutic concepts, including gene therapy, for rare genetic diseases of the central nervous system, peripheral nervous system and the kidney
- Biology, transport mechanisms and delivery across the blood brain barrier
- Biomarkers and imaging methodologies to facilitate disease diagnosis, evaluation of disease progression and therapeutic efficacy, or patient stratification, for MS, PD and other neurodegenerative diseases

**GENOMIC MEDICINE**
- Gene therapy applied primarily to rare diseases, rare blood disorders, CNS, musculoskeletal diseases and the kidney
- In vivo gene delivery in liver, brain, muscle and eye
- CNS gene delivery and/or neuromuscular gene delivery technologies such as AAV capsids that enable recombinant virus penetration of blood-brain barrier following intravenous, intracerebroventricular or intrathecal delivery approaches
- AAV platform and other gene delivery technology (non-AAV platform), such as virus-free gene delivery
- Triple transfection technology (TTX) as complementary/alternative approach to a robust AAV production method
- Technologies that improve CMC processes and productivity

**IMMUNO-ONCOLOGY**
- Allogenic NK cell therapy in solid tumors
- in situ generation of CAR T or CAR NK via delivery of targeted lipid nanoparticle carrying mRNA (or other methods)
- Mechanisms of innate and acquired resistance to checkpoint blockade
- Immuno-modulatory function of TGF-β
- Immune cell engagers (NK cells & T cells engagers)
- Immuno-Conjugates
- Intra-tumoral Treg depletion, modulation of immunosuppressive myeloid lineages
- Immune profiling methodologies in preclinical and clinical setting
- Novel translational models in immuno-oncology

**MOLECULAR ONCOLOGY**
Sanofi priority indications are breast, lung, multiple myeloma, prostate but also could be other cancers pending on target or modality.

- Novel targets and/or early drug discovery projects in molecularly-defined cancer populations and/or lineage
- Tumor induced immune suppression: regulation of anti-tumor immunity when the target is in tumor cells
- Tumors microenvironment targeting programs
- Modality: targeted protein degradation (PROTAC, Glue, monovalent degrader)

**BIOLOGICS RESEARCH**
- Specific tissue delivery of biologics
- In silico design / Computational biologics
- Intracellular biologics
- Multi specific protein formats